BR112022024262A2 - Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april - Google Patents

Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april

Info

Publication number
BR112022024262A2
BR112022024262A2 BR112022024262A BR112022024262A BR112022024262A2 BR 112022024262 A2 BR112022024262 A2 BR 112022024262A2 BR 112022024262 A BR112022024262 A BR 112022024262A BR 112022024262 A BR112022024262 A BR 112022024262A BR 112022024262 A2 BR112022024262 A2 BR 112022024262A2
Authority
BR
Brazil
Prior art keywords
treatment
april
methods
iga nephropathy
binding antibody
Prior art date
Application number
BR112022024262A
Other languages
English (en)
Inventor
Van De Laar Teun
Honarmand Somayeh
Dulos John
De Cock Eduard
Original Assignee
Chinook Therapeutics Inc
Aduro Biotech Holdings Europe B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinook Therapeutics Inc, Aduro Biotech Holdings Europe B V filed Critical Chinook Therapeutics Inc
Publication of BR112022024262A2 publication Critical patent/BR112022024262A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

MÉTODOS DE TRATAMENTO DE NEFROPATIA POR IGA COM UM ANTICORPO DE LIGAÇÃO A APRIL. Formulação e uso de anticorpos que se ligam a APRIL humana para o tratamento de condições relacionadas à superprodução ou depósito de IgA, incluindo Nefropatia por IgA.
BR112022024262A 2020-05-29 2021-05-28 Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april BR112022024262A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062704831P 2020-05-29 2020-05-29
PCT/US2021/035011 WO2021243298A1 (en) 2020-05-29 2021-05-28 Methods of treating iga nephropathy with an april binding antibody

Publications (1)

Publication Number Publication Date
BR112022024262A2 true BR112022024262A2 (pt) 2023-02-23

Family

ID=78722933

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024262A BR112022024262A2 (pt) 2020-05-29 2021-05-28 Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april

Country Status (11)

Country Link
US (1) US20210379183A1 (pt)
EP (1) EP4157339A1 (pt)
JP (1) JP2023527563A (pt)
KR (1) KR20230017223A (pt)
CN (1) CN115996748A (pt)
AU (1) AU2021279035A1 (pt)
BR (1) BR112022024262A2 (pt)
CA (1) CA3179812A1 (pt)
IL (1) IL298370A (pt)
MX (1) MX2022014995A (pt)
WO (1) WO2021243298A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
WO2023212518A1 (en) 2022-04-25 2023-11-02 Visterra, Inc. Antibody molecules to april and uses thereof
WO2024092240A1 (en) 2022-10-28 2024-05-02 Chinook Therapeutics, Inc. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
WO2024099272A1 (zh) * 2022-11-07 2024-05-16 信瑞诺医药（上海）有限公司 用于治疗IgA肾病的内皮素受体拮抗剂和糖皮质激素的组合

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
EA030313B1 (ru) * 2007-03-27 2018-07-31 Займодженетикс, Инк. СПОСОБ СНИЖЕНИЯ УРОВНЕЙ IgM, IgG И IgA У МЛЕКОПИТАЮЩИХ И КОМПОЗИЦИЯ ДЛЯ ОСУЩЕСТВЛЕНИЯ ЭТОГО СПОСОБА
SI2403528T1 (sl) * 2009-03-02 2016-07-29 Aduro Biotech Holdings, Europe B.V. Protitelesa proti proliferacijo inducirajočemu ligandu (april)
NL2014108B1 (en) * 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
UY36969A (es) * 2015-10-28 2017-05-31 Novartis Ag Composiciones y métodos para activar la señalización dependiente del estimulador del gen de interferon
TWI797073B (zh) * 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
HUE064655T2 (hu) * 2017-10-30 2024-04-28 Sanofi Biotechnology IL-4R antagonista asztma kezelésére vagy megelõzésére szolgáló eljárásban
CN110464842B (zh) * 2018-05-11 2022-10-14 信达生物制药(苏州)有限公司 包含抗pcsk9抗体的制剂及其用途

Also Published As

Publication number Publication date
WO2021243298A1 (en) 2021-12-02
AU2021279035A1 (en) 2023-02-02
MX2022014995A (es) 2023-02-09
JP2023527563A (ja) 2023-06-29
EP4157339A1 (en) 2023-04-05
CA3179812A1 (en) 2021-12-02
CN115996748A (zh) 2023-04-21
US20210379183A1 (en) 2021-12-09
KR20230017223A (ko) 2023-02-03
IL298370A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
BR112022024262A2 (pt) Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
BR112021011431A2 (pt) Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
BR112022017930A2 (pt) Anticorpos anticoronavírus e métodos de uso
BR112019008426A2 (pt) anticorpo biespecífico contra bcma e cd3 e um fármaco imunológico para uso combinado no tratamento de mieloma múltiplo
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
AR115418A1 (es) ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS
CR20150054A (es) Anticuerpos anti-cxcr5 humanizados derivados de los mismos y su uso
BR112022023088A2 (pt) Anticorpos contra sars-cov-2 e métodos de seleção e uso dos mesmos
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
BR112019004990A2 (pt) anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo
BR112021013397A2 (pt) Anticorpos anti-tigit
BR112019023898A2 (pt) método para tratamento de câncer gástrico, uso de um anticorpo e composição
BR112021008873A8 (pt) Formulação
BR112018072066A2 (pt) moléculas de ligação específicas para fcgamariia e uso das mesmas
ECSP21022299A (es) Anticuerpos de anti-cd33 y métodos para usarlos
BR112021021281A2 (pt) Anticorpo monoclonal que se liga especificamente ao gitr
DOP2022000129A (es) Anticuerpos contra la integrina alfa 11 beta 1
BR112018008900A2 (pt) composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
CO2021015254A2 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y métodos de uso de estos
ECSP21046332A (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano y los métodos para su uso
CL2021002866A1 (es) Tratamiento de la cefalea usando anticuerpos anti-cgrp.
AR120117A2 (es) Moléculas de unión a pd-1 y métodos de uso de las mismas
BR112022003635A2 (pt) Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso
BR112023016574A2 (pt) Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão